SK pharmteco is a global Contract Development and Manufacturing Organisation (CDMO) with state-of-the-art facilities in Korea, the US, France, and Ireland.
We are part of SK Inc., a Korean company with revenues of $99 billion in 2023. Our mission is to “produce and deliver life-changing therapies that improve patient outcomes and save lives”.
The Small Molecule facility in Swords has been a leader for over 60 years in the development, scale-up, and commercial manufacture of Active Pharmaceutical Ingredients (APIs) and chemical intermediates, delivering some of the world’s most important medicines...